evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

2 questions · 3 findings · 1 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 3 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Azo‐bonded and delayed‐release mesalamine (2 ‐ 3.2 g/day) vs placebo

Clinical remission or improvement · patients with Induction of remission or response in Crohn's disease

It is very uncertain whether azo‐bonded and delayed‐release mesalamine (2 ‐ 3.2 g/day) changes induction of remission or clinical improvement ‐ Asacol (3.2 g/day) compared with placebo (very low certainty).

2 findings from 1 review

Azo‐bonded and delayed‐release mesalamine (2 ‐ 3.2 g/day) vs placebo

Induction of remission (CDAI < 150 + decrease >=70) ‐ Asacol (3.2 g/day) · patients with Induction of remission or response in Crohn's disease

It is very uncertain whether azo‐bonded and delayed‐release mesalamine (2 ‐ 3.2 g/day) changes induction of remission (CDAI < 150 + decrease >=70) ‐ Asacol (3.2… compared with placebo (very low certainty).

1 finding from 1 review